Results 151 to 160 of about 6,571 (189)

Bouveret syndrome: a case report. [PDF]

J Surg Case Rep
Alhalabi M, Alsebai M, Alsamman M, Alhalabi MZ.   +3 more
europepmc   +1 more source

Effects of Dapagliflozin vs. Vildagliptin on the Lipid Profile of Patients With Uncontrolled Type 2 Diabetes. [PDF]

Cureus
Khanna S, Malik M, Ahmad R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Vildagliptin

Drugs, 2006
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is being evaluated in the treatment of patients with type 2 diabetes mellitus. It improves glycaemic control by inhibiting DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, prolonging incretin activity in response to ...
Sheridan, Henness, Susan J, Keam
  +6 more sources

Vildagliptin

Drugs, 2012
Susan J Keam
exaly   +2 more sources

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes [PDF]

Diabetes Care, 2011
Contains fulltext : 96512.pdf (Publisher’s version ) (Open Access)OBJECTIVE: To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes ...
Cornelis J Tack, Pleun C.M. van Poppel, Paul Smits   +2 more
exaly   +2 more sources

Vildagliptin

Reactions Weekly, 2023
  +6 more sources

Vildagliptin

Reactions Weekly, 2021
  +4 more sources

Vildagliptin

Reactions Weekly, 2017
Matthew M. Kim, Jennifer Jiang, Sutapa Ghosh   +2 more
  +4 more sources

Vildagliptin

Reactions Weekly, 2014
  +4 more sources